Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(anagrelide)
426 results
  • "Anagrelide-induced pulmonary arterial hypertension": a rare case of drug-induced pulmonary arterial hypertension. [Case Reports]
    Pulm Circ. 2019 Oct-Dec; 9(4):2045894019896682.Sumimoto K, Taniguchi Y, … Hirata KI
  • Pulmonary arterial hypertension can be associated with exposure to certain drugs or toxins. However, only a few cases of drug-induced pulmonary arterial hypertension have been previously reported. Anagrelide is an oral imidazoquinazoline agent that is prescribed for reducing elevated platelet counts in patients with myeloproliferative disorders. We report the case of a 70-year-old female patient …
  • [Essential thrombocythemia correctly diagnosed through the guidance of comprehensive genomic profiling]. [Case Reports]
    Rinsho Ketsueki. 2019; 60(12):1630-1634.Shibata S, Kitano T, … Arima N
  • In 2003, a 60-year-old man presenting with thrombocytosis was referred to our hospital. Laboratory tests revealed normal white blood cell count and hemoglobin level. Bone marrow examination showed an increased number of megakaryocytes with dysplasia. G-banded karyotype analysis revealed del (5q). Initially, the patient was diagnosed with myelodysplastic/myeloproliferative neoplasm (MDS/MPN), and …
  • Anagrelide Modulates Proplatelet Formation Resulting in Decreased Number and Increased Size of Platelets. [Journal Article]
    Hemasphere. 2019 Aug; 3(4):e268.Miyashita N, Onozawa M, … Teshima T
  • We retrospectively evaluated 48 essential thrombocythemia (ET) patients who were treated in our institute (male/female, 14/34, median age, 61.5 years). In 14 patients treated with anagrelide (ANA), the degree of platelet count reduction (median, -56.6%) was strongly correlated with increase of mean platelet volume (MPV) (median, +11.7%) (R = 0.777). This correlation was not observed in ET patient…
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: Anagrelide [BOOK]
    . National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)BOOK
  • Anagrelide is an antithrombotic and platelet reducing agent that is used to treat the thrombocythemia associated with myeloproliferative diseases. Anagrelide has had limited clinical use, but has not been linked to significant serum enzyme elevations during therapy or to instances of clinically apparent acute liver injury.
  • Cecal cancer with essential thrombocythemia treated by laparoscopic ileocecal resection: a case report. [Journal Article]
    Surg Case Rep. 2019 Jun 21; 5(1):101.Hiyoshi M, Nozawa H, … Ishihara S
  • CONCLUSIONS: To our knowledge, this is the first report of laparoscopic colectomy performed on an ET patient receiving anagrelide. Our report shows that complications such as bleeding or thrombosis can be avoided by anagrelide administration. Contrastingly, thrombocytopenia due to anagrelide intake should be considered when chemotherapy that could cause bone marrow suppression is administered.
  • Emerging drugs for essential thrombocythemia. [Review]
    Expert Opin Emerg Drugs. 2019 06; 24(2):93-105.Masarova L, Verstovsek S
  • Introduction: Despite our recent progress in the understanding of essential thrombocythemia (ET) pathogenesis, the therapeutic management of this disease has remained largely unchanged in the past decades. Treatment has mostly focused on decreasing the risk of complications, especially prevention of thrombotic or hemorrhagic events. Areas covered: Over recent years, the treatment options of ET ha…
  • Contemporary management of essential thrombocythemia in children. [Review]
    Expert Rev Hematol. 2019 05; 12(5):367-373.Randi ML, Bertozzi I, Putti MC
  • Essential thrombocythemia (ET) is a disease which is extremely rare in children. Only recently, data on pediatric ET have become available. Areas covered: In children with sustained platelet count over 450 x 109/L, secondary thrombocytosis must be ruled out. ET workup comprehends research of JAK2V617F, CALR and MPL mutations and bone marrow biopsy (BM). In asymptomatic children wait and watch is …
  • [Essential thrombocythemia accompanied by adrenal infarction]. [Case Reports]
    Rinsho Ketsueki. 2019; 60(2):106-111.Iemura T, Mano C, … Itoh M
  • A 64-year-old man presented to the emergency department with sudden-onset upper abdominal pain and pain in the left chest area. His platelet count was 121.7×104/µl. Computed tomography (CT) showed bilateral adrenal swelling and inflammation of the adjacent tissue. Diffusion-weighted magnetic resonance imaging (MRI) showed hyperintensity in the bilateral adrenal glands. The patient was diagnosed w…
  • Acute ischemic stroke in the setting of essential thrombocytemia (clinical cases). [Case Reports]
    Ter Arkh. 2018 Aug 17; 90(7):102-104.Tanashyan MM, Kuznetsova PI, … Melikyan AL
  • This article describes several clinical cases of acute ischemic stroke among patients suffering from essential thrombocytemia. Ambiguity of etiological factors of stroke is demonstrated among patients with this pathology. Thrombocytosis and high allele load in the Jak2 gene play an important role (even with normal platelet count) in progression of cerebrovascular disease. Also the question of eff…
  • Therapeutic thrombocytapheresis for extreme thrombocytosis after chemotherapy in essential thrombocytosis. [Case Reports]
    J Clin Apher. 2019 Aug; 34(4):503-506.Almeida-Dias R, Garrote M, … Lozano M
  • Essential thrombocytosis (ET) is a chronic myeloproliferative neoplasm characterized by the presence of thrombocytosis and it can be complicated by thrombotic and/or hemorrhagic events. Treatment options include low-dose aspirin and cytoreductive agents such as hydroxyurea. In cases of extreme thrombocytosis, therapeutic thrombocytapheresis can be a useful procedure. We present a case of a 61-yea…
  • Anagrelide for Gastrointestinal Stromal Tumor. [Journal Article]
    Clin Cancer Res. 2019 03 01; 25(5):1676-1687.Pulkka OP, Gebreyohannes YK, … Joensuu H
  • CONCLUSIONS: PDE3A and PDE3B are frequently expressed in GIST. Anagrelide had anticancer efficacy in GIST xenograft models and warrants further testing in clinical trials.
New Search Next